Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Cell contact and Nf2/Merlin-dependent regulation of TEAD palmitoylation and activity.

Kim NG, Gumbiner BM.

Proc Natl Acad Sci U S A. 2019 May 14;116(20):9877-9882. doi: 10.1073/pnas.1819400116. Epub 2019 May 1.

PMID:
31043565
2.

Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial.

Gumbiner B, Esteves B, Dell V, Joh T, Garzone PD, Forgie A, Udata C.

Endocrine. 2018 Nov;62(2):371-380. doi: 10.1007/s12020-018-1597-1. Epub 2018 Sep 10.

PMID:
30203123
3.

E-cadherin in contact inhibition and cancer.

Mendonsa AM, Na TY, Gumbiner BM.

Oncogene. 2018 Aug;37(35):4769-4780. doi: 10.1038/s41388-018-0304-2. Epub 2018 May 21. Review.

4.

The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.

Gumbiner B, Joh T, Liang H, Wan H, Levisetti M, Vana AM, Shelton DL, Forgues P, Billotte S, Pons J, Baum CM, Garzone PD.

Cardiovasc Ther. 2018 Feb;36(1). doi: 10.1111/1755-5922.12309. Epub 2017 Nov 23.

PMID:
29078037
5.

A Rare Case of Chondroblastoma with Revision After Graft RejectionA Case Report.

Gumbiner B, Jacobsen E, Stancukas M, Nguyen N.

J Am Podiatr Med Assoc. 2017 Sep;107(5):440-445. doi: 10.7547/15-216.

PMID:
29077506
6.

Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.

Fazio S, Robertson DG, Joh T, Wan H, Riel T, Forgues P, Baum CM, Garzone PD, Gumbiner B.

Cardiovasc Ther. 2018 Feb;36(1). doi: 10.1111/1755-5922.12308. Epub 2017 Nov 25.

PMID:
29057618
7.

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.

Wan H, Gumbiner B, Joh T, Riel T, Udata C, Forgues P, Garzone PD.

Clin Ther. 2017 Nov;39(11):2243-2259.e5. doi: 10.1016/j.clinthera.2017.09.009. Epub 2017 Oct 14.

PMID:
29037448
8.

A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development.

Udata C, Garzone PD, Gumbiner B, Joh T, Liang H, Liao KH, Williams JH, Meng X.

J Clin Pharmacol. 2017 Jul;57(7):855-864. doi: 10.1002/jcph.867. Epub 2017 Feb 9.

PMID:
28181260
9.

A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy.

Levisetti M, Joh T, Wan H, Liang H, Forgues P, Gumbiner B, Garzone PD.

Clin Transl Sci. 2017 Jan;10(1):3-11. doi: 10.1111/cts.12430. Epub 2016 Nov 17.

10.

Roles for E-cadherin cell surface regulation in cancer.

Petrova YI, Schecterson L, Gumbiner BM.

Mol Biol Cell. 2016 Nov 1;27(21):3233-3244. Epub 2016 Aug 31.

11.

Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis.

Li H, Gumbiner BM.

Mamm Genome. 2016 Dec;27(11-12):556-564. Epub 2016 Sep 6.

12.

Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab.

Williams JH, Hutmacher MM, Zierhut ML, Becker JC, Gumbiner B, Spencer-Green G, Melia LA, Liao KH, Suster M, Yin D, Li R, Meng X.

Br J Clin Pharmacol. 2016 Dec;82(6):1568-1579. doi: 10.1111/bcp.13094. Epub 2016 Sep 22.

13.

A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.

Cohen S, Emery P, Greenwald M, Yin D, Becker JC, Melia LA, Li R, Gumbiner B, Thomas D, Spencer-Green G, Meng X.

Br J Clin Pharmacol. 2016 Jul;82(1):129-38. doi: 10.1111/bcp.12916. Epub 2016 Apr 29.

14.

Microtubules Inhibit E-Cadherin Adhesive Activity by Maintaining Phosphorylated p120-Catenin in a Colon Carcinoma Cell Model.

Maiden SL, Petrova YI, Gumbiner BM.

PLoS One. 2016 Feb 4;11(2):e0148574. doi: 10.1371/journal.pone.0148574. eCollection 2016.

15.

Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway.

Kim NG, Gumbiner BM.

J Cell Biol. 2015 Aug 3;210(3):503-15. doi: 10.1083/jcb.201501025. Epub 2015 Jul 27.

16.

Allosteric Regulation of E-Cadherin Adhesion.

Shashikanth N, Petrova YI, Park S, Chekan J, Maiden S, Spano M, Ha T, Gumbiner BM, Leckband DE.

J Biol Chem. 2015 Aug 28;290(35):21749-61. doi: 10.1074/jbc.M115.657098. Epub 2015 Jul 14.

17.

Cadherin-6B is required for the generation of Islet-1-expressing dorsal interneurons.

Park KS, Gumbiner BM.

Biochem Biophys Res Commun. 2015 Apr 10;459(3):504-8. doi: 10.1016/j.bbrc.2015.02.136. Epub 2015 Mar 5.

18.

Clinical considerations for the development of biosimilars in oncology.

Socinski MA, Curigliano G, Jacobs I, Gumbiner B, MacDonald J, Thomas D.

MAbs. 2015;7(2):286-93. doi: 10.1080/19420862.2015.1008346. Review.

19.

N-cadherin mediates the migration of MCF-10A cells undergoing bone morphogenetic protein 4-mediated epithelial mesenchymal transition.

Park KS, Dubon MJ, Gumbiner BM.

Tumour Biol. 2015 May;36(5):3549-56. doi: 10.1007/s13277-014-2991-9. Epub 2014 Dec 28.

20.

The Hippo-YAP signaling pathway and contact inhibition of growth.

Gumbiner BM, Kim NG.

J Cell Sci. 2014 Feb 15;127(Pt 4):709-17. doi: 10.1242/jcs.140103.

21.

Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1.

Fan R, Kim NG, Gumbiner BM.

Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2569-74. doi: 10.1073/pnas.1216462110. Epub 2013 Jan 28.

22.
23.

Conformational epitopes at cadherin calcium-binding sites and p120-catenin phosphorylation regulate cell adhesion.

Petrova YI, Spano MM, Gumbiner BM.

Mol Biol Cell. 2012 Jun;23(11):2092-108. doi: 10.1091/mbc.E11-12-1060. Epub 2012 Apr 18.

24.

p53 and microRNA-34 are suppressors of canonical Wnt signaling.

Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY, Kang SE, Cha SY, Ryu JK, Na JM, Park C, Kim K, Lee S, Gumbiner BM, Yook JI, Weiss SJ.

Sci Signal. 2011 Nov 1;4(197):ra71. doi: 10.1126/scisignal.2001744.

25.

Axial protocadherin (AXPC) regulates cell fate during notochordal morphogenesis.

Yoder MD, Gumbiner BM.

Dev Dyn. 2011 Nov;240(11):2495-504. doi: 10.1002/dvdy.22754. Epub 2011 Sep 29.

26.

E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components.

Kim NG, Koh E, Chen X, Gumbiner BM.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11930-5. doi: 10.1073/pnas.1103345108. Epub 2011 Jul 5.

27.

Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome.

Bays HE, Shah A, Macdonell G, Taggart WV, Gumbiner B.

Metab Syndr Relat Disord. 2011 Apr;9(2):135-42. doi: 10.1089/met.2010.0068. Epub 2010 Nov 30.

PMID:
21117970
28.

Cadherin 6B induces BMP signaling and de-epithelialization during the epithelial mesenchymal transition of the neural crest.

Park KS, Gumbiner BM.

Development. 2010 Aug;137(16):2691-701. doi: 10.1242/dev.050096. Epub 2010 Jul 7.

29.

A protocadherin-cadherin-FLRT3 complex controls cell adhesion and morphogenesis.

Chen X, Koh E, Yoder M, Gumbiner BM.

PLoS One. 2009 Dec 22;4(12):e8411. doi: 10.1371/journal.pone.0008411.

30.

Regulation of protein stability by GSK3 mediated phosphorylation.

Xu C, Kim NG, Gumbiner BM.

Cell Cycle. 2009 Dec 15;8(24):4032-9. Epub 2009 Dec 17.

31.

Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy.

Krishna R, Gumbiner B, Stevens C, Musser B, Mallick M, Suryawanshi S, Maganti L, Zhu H, Han TH, Scherer L, Simpson B, Cosgrove D, Gottesdiener K, Amatruda J, Rolls BJ, Blundell J, Bray GA, Fujioka K, Heymsfield SB, Wagner JA, Herman GA.

Clin Pharmacol Ther. 2009 Dec;86(6):659-66. doi: 10.1038/clpt.2009.167. Epub 2009 Sep 9.

PMID:
19741604
32.

Identification of targets of the Wnt pathway destruction complex in addition to beta-catenin.

Kim NG, Xu C, Gumbiner BM.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5165-70. doi: 10.1073/pnas.0810185106. Epub 2009 Mar 16.

33.

Convergence and extension at gastrulation require a myosin IIB-dependent cortical actin network.

Skoglund P, Rolo A, Chen X, Gumbiner BM, Keller R.

Development. 2008 Aug;135(14):2435-44. doi: 10.1242/dev.014704. Epub 2008 Jun 11.

34.

Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.

Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B, Musliner TA.

Metabolism. 2008 Jun;57(6):796-801. doi: 10.1016/j.metabol.2008.01.026.

PMID:
18502262
35.

The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.

Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohórquez SM, Stoch A, Stevens C, Fong TM, De Lepeleire I, Cilissen C, Cote J, Rosko K, Gendrano IN 3rd, Nguyen AM, Gumbiner B, Rothenberg P, de Hoon J, Bormans G, Depré M, Eng WS, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves RJ, Wagner J, Gottesdiener K, Amatruda JM, Heymsfield SB.

Cell Metab. 2008 Jan;7(1):68-78. doi: 10.1016/j.cmet.2007.11.012.

36.
37.

Structural elements necessary for oligomerization, trafficking, and cell sorting function of paraxial protocadherin.

Chen X, Molino C, Liu L, Gumbiner BM.

J Biol Chem. 2007 Nov 2;282(44):32128-37. Epub 2007 Sep 6.

38.

E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions.

Perrais M, Chen X, Perez-Moreno M, Gumbiner BM.

Mol Biol Cell. 2007 Jun;18(6):2013-25. Epub 2007 Mar 28.

39.

Cadherin conformations associated with dimerization and adhesion.

Tsuiji H, Xu L, Schwartz K, Gumbiner BM.

J Biol Chem. 2007 Apr 27;282(17):12871-82. Epub 2007 Mar 8.

40.

Characterization of a 60S complex of the adenomatous polyposis coli tumor suppressor protein.

Mahadevaiyer S, Xu C, Gumbiner BM.

Biochim Biophys Acta. 2007 Feb;1773(2):120-30. Epub 2006 Oct 20.

41.

Crosstalk between different adhesion molecules.

Chen X, Gumbiner BM.

Curr Opin Cell Biol. 2006 Oct;18(5):572-8. Epub 2006 Jul 21.

PMID:
16859906
42.
43.

Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.

McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson G, Davies MJ, Mitchel YB, Gumbiner B.

J Am Coll Cardiol. 2006 Apr 18;47(8):1584-7. Epub 2006 Mar 30.

44.

The mammalian Scribble polarity protein regulates epithelial cell adhesion and migration through E-cadherin.

Qin Y, Capaldo C, Gumbiner BM, Macara IG.

J Cell Biol. 2005 Dec 19;171(6):1061-71. Epub 2005 Dec 12.

45.

Regulation of cadherin-mediated adhesion in morphogenesis.

Gumbiner BM.

Nat Rev Mol Cell Biol. 2005 Aug;6(8):622-34. Review.

PMID:
16025097
46.

Coordinate gene regulation by two different catenins.

Gumbiner BM.

Dev Cell. 2005 Jun;8(6):795-6.

47.

Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.

Masana L, Mata P, Gagné C, Sirah W, Cho M, Johnson-Levonas AO, Meehan A, Troxell JK, Gumbiner B; Ezetimibe Study Group.

Clin Ther. 2005 Feb;27(2):174-84.

PMID:
15811480
48.

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.

Farnier M, Freeman MW, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, Gumbiner B; Ezetimibe Study Group.

Eur Heart J. 2005 May;26(9):897-905. Epub 2005 Mar 21.

PMID:
15781429
49.

Distinct molecular forms of beta-catenin are targeted to adhesive or transcriptional complexes.

Gottardi CJ, Gumbiner BM.

J Cell Biol. 2004 Oct 25;167(2):339-49. Epub 2004 Oct 18.

50.

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.

Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B.

Curr Med Res Opin. 2004 Sep;20(9):1437-45.

PMID:
15383192

Supplemental Content

Loading ...
Support Center